Adagrasib

Today is World Lung Cancer Day.

The FDA granted accelerated approval adagrasib with cetuximab for the treatment of KRASG12C -mutated locally advanced or metastatic colorectal cancer, according to a press release from the agency.

In this edition, screening program identifies airways disease in previously undiagnosed COPD, positive results show benefits of subcutaneous bispecifics and more.

CHICAGO — Individuals with KRAS-mutant lung cancer treated with adagrasib experienced significantly prolonged PFS compared with docetaxel, randomized study results presented at ASCO Annual Meeting showed.

Adagrasib monotherapy improved PFS and overall response rate among adults with pretreated locally advanced or metastatic non-small cell lung cancer harboring a KRASG12C

MADRID — Pasi Jänne, MD, PhD, discussed the “encouraging” clinical activity of adagrasib with pembrolizumab in patients with KRAS G12C-mutated advanced non-small cell lung cancer in a video interview with Healio at ESMO Congress.

In this edition, addition of tumor treating fields extends OS; atezolizumab-bevacizumab survival rates; screening leads to more stage I, less stage IV disease incidence, and more.

The FDA granted accelerated approval to adagrasib for certain adults with non-small cell lung cancer.

2022 has brought many research updates and approvals in lung cancer.

Adagrasib alone and in combination with cetuximab exhibited promising efficacy compared with historical outcomes among heavily pretreated patients with advanced colorectal cancer who had KRASG12C mutations.